Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

BELLICUN Form 4 July 06, 20	M PHARMACEU	TICALS,	INC									
FORM Check to if no lo subject Section Form 4 Form 5 obligati may co	VI 4 this box nger to 16. or filed put Section 170	MENT OI rsuant to S (a) of the I	Wa F CHAN Section Public U	ashington NGES IN SECUI 16(a) of th	h, D.C. 20 BENEF RITIES ne Securi Iding Con	9549 TCIAI ties Ex npany	L OW	COMMISSIC NERSHIP O e Act of 1934 f 1935 or Sec 40)F 4,	OMB A OMB Number: Expires: Estimated burden hou response	irs per	1)5
1. Name and Address of Reporting Person <u>*</u> Moseley Ken			2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [BLCM]				g	Issuer		Reporting Person(s) to k all applicable) 10% Owner		
	. , , ,			of Earliest T Day/Year) 2017	ransaction			X Officer (below) Sr. V		tle Oth below) General Co	er (specify Insel	
(Street) 4. If Am			² Amendment, Date Original d(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Tat	ole I - Non-J	Derivative	Securi	ties Acq	uired, Dispose	d of, o	or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	ed Date, if	3.	4. Securit onAcquired Disposed (Instr. 3,	ies (A) or of (D) 4 and 5) (A) or	5 S B C F R T	. Amount of ecurities Beneficially Owned following teported fransaction(s) Instr. 3 and 4)	6. C For (D) (I)	Ownership m: Direct or Indirect str. 4)	7. Nature of Indirect	
Reminder: Ro	eport on a separate line	e for each cl	ass of sec		ficially ow Perso inforr requi	ned dire ons when nation red to r	ectly or i o respo contai respon	indirectly. ond to the col ned in this for d unless the f y valid OMB of	rm ar form	e not	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	ate, if TransactiorDerivative Expiration Date Code Securities (Month/Day/Year)		ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S ()	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 11.7	07/03/2017		A	26,250	<u>(1)</u>	07/02/2027	Common Stock	26,250	
Stock Option (right to buy)	\$ 11.7	07/03/2017		A	42,000	<u>(1)</u>	07/02/2027	Common Stock	42,000	

Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
hepoting of her runner runners	Director	10% Owner	Officer	Other			
Moseley Ken C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON, TX 77030			Sr. VP and General Counsel				
Signatures							

/s/ Ken Moseley 07/06/2017 J.D. **Signature of

Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- 25% of the shares subject to the stock option vest and become exercisable on January 1, 2018, and the remaining shares subject to the (1) stock option vest and become exercisable in 36 equal monthly installments thereafter.

The Reporting Person's spouse is Annemarie Moseley, Consultant to Bellicum, formerly COO/EVP Clinical Development. The Reporting (2) Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Γ